Skip to main content
. Author manuscript; available in PMC: 2012 Oct 17.
Published in final edited form as: Clin Lung Cancer. 2010 Jul 1;11(4):228–237. doi: 10.3816/CLC.2010.n.029

Fig 3.

Fig 3

Survival analysis in a randomized phase IIB trial of BLP25 liposome vaccine in the subset of non-small cell lung cancer patients with stage IIIB locoregional disease. Median OS 13.3 months for best supportive care compared with not reached for BLP25 vaccine.

Reprinted with permission. © 2008 American Society of Clinical Oncology. All rights reserved. Butts C, et al.. J Clin Oncol 2005;23:6674–81.